Results 1 to 10 of about 17,265 (194)

Impact of anticancer drugs on the therapeutic efficacy and side effects of hepatic arterial embolization for hepatocellular carcinoma

JGH Open, 2023
Background and Aim Transcatheter arterial chemoembolization (TACE) using various anticancer drugs is often performed to treat hepatocellular carcinoma (HCC).
Hironobu Ihira, Tetsuo Sonomura, Ayano Makitani, Kazuhiro Makitani, Kodai Fukuda, Ryota Tanaka, Takao Koyama, Hirotatsu Sato, Ke Wan, Masaki Ueno, Yoshiyuki Ida, Nobuyuki Kawai, Hiroki Minamiguchi   +12 more
doaj   +1 more source

Transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma: A real-world propensity score-matched study

Tzu Chi Medical Journal, 2022
Objectives: Transarterial chemoembolization (TACE) or sorafenib may prolong survival in patients with unresectable hepatocellular carcinoma (HCC); however, whether their combination prolongs survival than TACE alone remains controversial.
Tzu-Rong Peng, Ta-Wei Wu, Chao-Chuan Wu, Sou-Yi Chang, Cheng-Yi Chan, Ching-Sheng Hsu   +5 more
doaj   +1 more source

Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients

The Korean Journal of Gastroenterology, 2020
Background/Aims: A switch to systemic therapy, such as sorafenib, should be considered for hepatocellular carcinoma (HCC) patients refractory to transarterial chemoembolization (TACE).
Kang Hyun Park, Jeong Han Kim, Won Hyeok Choe, So Young Kwon, Byung Chul Yoo, Jin Ho Hwang, Sang Woo Park, Young Jun Kim, Hee Sun Park, Mi Hye Yu, Hae Jeong Jeon   +10 more
doaj   +1 more source

c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis

Hepatology, EarlyView., 2022
In response to genotoxic injury, c‐Rel upregulates ATM‐Chk2‐p53 pathway DNA damage proteins to limiting hepatocarcinogenesis. Abstract Background and Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a
Jack Leslie, Jill E. Hunter, Amy Collins, Amelia Rushton, Lauren G. Russell, Erik Ramon‐Gil, Maja Laszczewska, Misti McCain, Marco Y. W. Zaki, Amber Knox, Yixin Seow, Laura Sabater, Daniel Geh, Neil D. Perkins, Helen L. Reeves, Dina Tiniakos, Derek A. Mann, Fiona Oakley   +17 more
wiley   +1 more source

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis

Technology in Cancer Research & Treatment, 2022
Introduction: This retrospective study aimed to compare the efficacy and safety of transarterial chemoembolization plus lenvatinib and programmed death 1 (PD-1) inhibitors versus transarterial chemoembolization plus lenvatinib or sorafenib in patients ...
Shu Zhao MD, Minhang Zhou MD, Peng Wang PhD, Jing Yang PhD, Dong Zhang PhD, Fan Yin PhD, Peng Song PhD   +6 more
doaj   +1 more source

Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization [PDF]

The Korean Journal of Internal Medicine, 2019
Background/Aims Transarterial chemoembolization (TACE) is performed for single hepatocellular carcinoma (HCC) that are not eligible for surgery or ablation therapy.
Min Young Baek, Jeong-Ju Yoo, Soung Won Jeong, Jae Young Jang, Yong Kwon Kim, Shin Ok Jeong, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim, Yong Jae Kim, Su Yeon Park   +14 more
doaj   +1 more source

The value of ADC calculations in the assessment of the early response of hepatocellular carcinoma (HCC) to trans arterial catheter chemoembolization (TACE). [PDF]

Minia Journal of Medical Research, 2019
Transcatheter arterial chemoembolization (TACE) is a well-accepted method for Treatment of unresectable hepatocellular carcinoma (HCC). Determining the success of treatment by imaging studies would help to guide subsequent therapeutic planning ...
Kareem Megahed, Mostafa Mostafa, Hosny Abd Elghany   +2 more
doaj   +1 more source

Combination of transcatheter arterial chemoembolization and portal vein embolization for patients with hepatocellular carcinoma: a review

World Journal of Surgical Oncology, 2021
Background Transcatheter arterial chemoembolization has been widely used in patients with hepatocellular carcinoma. However, double blood supply and the existence of portal vein tumor thrombus influence the efficacy of transcatheter arterial ...
Zhiying Shao, Xin Liu, Chanjuan Peng, Liping Wang, Dong Xu   +4 more
doaj   +1 more source

Liver Abscess Formation after Radiofrequency Ablation of Hepatocellular Carcinoma

대한영상의학회지, 2017
Purpose: To determine prognostic factors for the development of liver abscess formation in patients with hepatocellular carcinoma (HCC) treated with radiofrequency ablation (RFA) focusing on the history of multiple prior sessions of transarterial ...
Juwon Kim, Mi Young Kim, Yun Ku Cho
doaj   +1 more source

Biliary complications after transcatheter arterial chemoembolization for hepatocellular carcinoma

International Journal of Gastrointestinal Intervention, 2020
Transarterial chemoembolization (TACE) is considered an effective procedure for liver malignancy. Although the majority of TACE related complications can be treated conservatively, appropriate therapeutic interventions, such as percutaneous/endoscopic ...
Yoon Suk Lee, Kyung-Ah Kim
doaj   +1 more source